Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.49
    +0.13 (+0.21%)

    Market Cap: $5.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    PTC Therapeutics Inc (PTCT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    PTC Therapeutics (PTCT) trades at 5.2x sales. Its P/S of 5.2x is above its 5-year median of 3.7x. Its forward P/E is 19.0x.

    Current Multiples

    Its enterprise value is 31.0x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E19.0x
    Price to sales5.2x
    EV/EBITDA31.0x
    PEGN/A
    FCF yield-0.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is in line.

    MultipleCurrent5-year median10-year median
    P/S5.2x3.7x5.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 2.2x in 2023 to 10.5x in 2020.

    Year endPriceP/EP/SP/B
    2025$75.9610.0x3.4xN/A
    2024$45.14N/A4.3xN/A
    2023$27.56N/A2.2xN/A
    2022$38.17N/A3.9xN/A
    2021$39.83N/A5.2xN/A
    2020$61.03N/A10.5x8.5x
    2019$48.03N/A8.8x4.6x
    2018$34.32N/A6.0x4.9x
    2017$16.68N/A3.4x4.5x
    2016$10.91N/A4.5x3.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PTCT

    What is PTCT's forward P/E ratio?

    PTC Therapeutics has a forward P/E ratio of 19.0x.

    Is PTCT stock overvalued?

    GNG's valuation label for PTCT is Fairly valued.

    What is PTCT's price to sales ratio?

    PTC Therapeutics has a price to sales ratio of 5.2x.